Pfizer Abandons Ionis’ Cardiovascular and High Triglyceride Program
Summary : Pfizer and Ionis Pharmaceuticals announced that the former is abandoning its vupanorsen program for cardiovascular (CV) risk reduction and severe…
Summary : Pfizer and Ionis Pharmaceuticals announced that the former is abandoning its vupanorsen program for cardiovascular (CV) risk reduction and severe…
Synopsis : A new study has found that nutritional supplements taken to boost athletic performance can pose risks to the heart of…
Synopsis: BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (Vosoritide) for Injection, indicated…
Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…
SYNOPSIS: VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s…
SUMMARY: The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organizations have partnered to…